Thrombotic microangiopathy and anti-VEGF agents [5]

Nephrology Dialysis Transplantation

Volumn 22, Issue 5, 2007, Pages 1481-1482

  Izzedine, Hassane ^a   Brocheriou, Isabelle ^a   Deray, Gilbert ^a   Rixe, Olivier ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CORTICOSTEROID; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; VASCULOTROPIN INHIBITOR;

ADULT; ALBUMIN BLOOD LEVEL; CASE REPORT; CREATININE BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GLOMERULUS CAPILLARY; HEMATURIA; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; KIDNEY BIOPSY; LEG EDEMA; LETTER; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; OVARY CANCER; PERCUTANEOUS BIOPSY; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREA NITROGEN BLOOD LEVEL;

BIOPSY; CAMPTOTHECIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY GLOMERULUS; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34447520277     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl565     Document Type: Letter

References (4)

1. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434
2. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
3. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191
4. Sugimoto H, Hamano Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608